Sanofi: agreement with Washington for a Covid vaccine
(CercleFinance.com) - Sanofi and GSK announce their establishment of a collaboration with the US government to accelerate the development and manufacture of a recombinant protein-based vaccine against Covid-19.
The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant protein technology that Sanofi used to produce an influenza vaccine and on the adjuvant for pandemic use developed by GSK.
The US government will provide up to 2.1 billion dollars, more than half of which will support development activities, with the remainder being used for large-scale manufacture and delivery of 100 million initial doses of the vaccine.
Copyright (c) 2020 CercleFinance.com. All rights reserved.